<code id='58B36B22A7'></code><style id='58B36B22A7'></style>
    • <acronym id='58B36B22A7'></acronym>
      <center id='58B36B22A7'><center id='58B36B22A7'><tfoot id='58B36B22A7'></tfoot></center><abbr id='58B36B22A7'><dir id='58B36B22A7'><tfoot id='58B36B22A7'></tfoot><noframes id='58B36B22A7'>

    • <optgroup id='58B36B22A7'><strike id='58B36B22A7'><sup id='58B36B22A7'></sup></strike><code id='58B36B22A7'></code></optgroup>
        1. <b id='58B36B22A7'><label id='58B36B22A7'><select id='58B36B22A7'><dt id='58B36B22A7'><span id='58B36B22A7'></span></dt></select></label></b><u id='58B36B22A7'></u>
          <i id='58B36B22A7'><strike id='58B36B22A7'><tt id='58B36B22A7'><pre id='58B36B22A7'></pre></tt></strike></i>

          knowledge

          knowledge

          author:fashion    Page View:6847
          Sammy Kimball for STAT

          Can Novavax finally get it right? What’s a “triple-G” drug? And is Novo Nordisk losing ground?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Elaine Chen joins us to explain how the era of Wegovy could be short-lived in light of powerful new weight-loss medicines from Eli Lilly. Then, John Jacobs, the new CEO of Novavax, stops by to explain his plan to right the ship at a company that has struggled to make the most of its potent Covid-19 vaccine.

          advertisement

          For more on what we cover, here’s the news on Lilly; here’s more on Novavax; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          knowledge

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          Telehealth startups turn to complex chronic diseases
          Telehealth startups turn to complex chronic diseases

          MollyFergusonforSTATIfherneurologistmovedtoChina,LaurenStilessaysshe’dfollowhimthere.“There’ssofewdo

          read more
          At least 13 dead in Texas as scorching temps continue
          At least 13 dead in Texas as scorching temps continue

          1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

          read more

          Shionogi licenses Pompe disease therapy from Maze Therapeutics

          MazeTherapeuticsCEOJasonColomaCourtesyAfterseeingitslastdealgobustinthefaceofregulatoryscrutiny,Maze